Telehealth Advance Care Planning for Myeloid Leukemia
(SICP RCT Trial)
Trial Summary
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications.
What data supports the effectiveness of this treatment for Telehealth Advance Care Planning for Myeloid Leukemia?
The Serious Illness Care Program (SICP), when adapted for telehealth, has been shown to help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) share their values with their care team, potentially improving end-of-life care. Additionally, in oncology settings, the SICP has led to more frequent and better-quality conversations about patient goals and values, reducing anxiety and depression among patients with advanced cancer.12345
Is the Telehealth Advance Care Planning for Myeloid Leukemia safe for humans?
The Serious Illness Care Program (SICP), which has been adapted for telehealth, is a communication intervention aimed at improving conversations about values for patients with serious illnesses. It has been shown to reduce anxiety and depression in patients with advanced cancer, suggesting it is generally safe for human use.12356
How is the Telehealth Serious Illness Care Program treatment different from other treatments for myeloid leukemia?
The Telehealth Serious Illness Care Program is unique because it focuses on improving communication about personal values and goals for patients with serious illnesses like myeloid leukemia, using telehealth to facilitate these conversations. Unlike traditional treatments that focus on medical interventions, this program helps align patient care with what matters most to them, providing a more personalized approach to end-of-life care.13789
What is the purpose of this trial?
The objective of this project is to conduct a pilot randomized trial to assess the preliminary efficacy of a telehealth-delivered Serious Illness Care Program on healthcare communication, patient anxiety and distress, as well as completion of advance directives (specifically MOLST and healthcare proxy forms) for older patients with acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies.
Research Team
Kah Poh Loh, MD
Principal Investigator
University of Rochester
Eligibility Criteria
This trial is for individuals aged 60 or older with certain blood disorders, including acute myeloid leukemia and myelodysplastic syndrome. Participants must be receiving outpatient care, able to give informed consent, and speak English.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Telehealth Intervention
Participants receive the telehealth-delivered Serious Illness Care Program, including the Serious Illness Conversation Guide and education materials
Follow-up
Participants are monitored for healthcare communication, anxiety, and distress
Long-term Follow-up
Participants are monitored for completion of advance directives and other long-term outcomes
Treatment Details
Interventions
- Education Control
- Telehealth Serious Illness Care Program
Telehealth Serious Illness Care Program is already approved in United States for the following indications:
- Advance care planning for serious illnesses such as acute myeloid leukemia, myelodysplastic syndrome, and similar myeloid malignancies
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Rochester
Lead Sponsor